Jubliant Life Sciences receives ANDA final approval for Levofloxacin

Jubliant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval for Levofloxacin tablets, 250mg and 500mg, the generic version of Levaquin Tablets. It is used in treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax. The market size of Levofloxacin is estimated at USD 28 million.

Company Profile : Jubilant Life Sciences Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.